Evidence map›Paper›PMID 33189146›Full record

ArticleCritical care (London, England)2020

Mode of bacterial killing affects the inflammatory response and associated organ dysfunctions in a porcine E. coli intensive care sepsis model.

Paul Skorup, Lisa Maudsdotter, Miklós Lipcsey, Anders Larsson, Jan Sjölin

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Critical care (London, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05511129 (Tolerance and Efficacy of Amiklin Administration During Nosocomial Infections Complicating COVID-19 in the ICU), which is not on this map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05511129 unknown statusnot on this mapstarted 2022, after this paper: background citation

Tolerance and Efficacy of Amiklin Administration During Nosocomial Infections Complicating COVID-19 in the ICU

TypeobservationalSponsorFondation Hôpital Saint-JosephRan2022 to 2023Enrolled1,053ConditionsCOVID-19, Nosocomial Infection
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Article
  5. An ovine septic shock model of live bacterial infusion.Intensive care medicine experimental · 2024
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Paul SkorupDepartment of Medical Sciences, Section of Infectious Diseases, Uppsala University, 751 85, Uppsala, SE, Sweden. paul.skorup@medsci.uu.se.ORCID 0000-0002-5407-6612
Lisa MaudsdotterDepartment of Molecular Biosciences, The Wenner-Gren Institute, Stockholm University, Stockholm, Sweden.
Miklós LipcseyDepartment of Surgical Sciences, Hedenstierna Laboratory, Anesthesiology & Intensive Care, Uppsala University, Uppsala, Sweden.
Anders LarssonDepartment of Medical Sciences, Section of Clinical Chemistry, Uppsala University, Uppsala, Sweden.
Jan SjölinDepartment of Medical Sciences, Section of Infectious Diseases, Uppsala University, 751 85, Uppsala, SE, Sweden.
Uppsala University · SEStockholm University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSepsis is often treated with penicillin-binding protein 3 (PBP-3) acting β-lactam antibiotics, such as piperacillin-tazobactam, cefotaxime, and meropenem. They cause considerable bacterial structural changes and have in vitro been associated with an increased inflammatory response. In a clinically relevant large animal sepsis model, our primary aim was to investigate whether bacteria killed by a PBP-3-active antibiotic has a greater effect on the early inflammatory response and organ dysfunction compared with corresponding amounts of live or heat-killed bacteria. A secondary aim was to determine whether the addition of an aminoglycoside could mitigate the cefuroxime-induced response.

methodKilled or live Escherichia coli were administrated as a 3-h infusion to 16 healthy pigs in a prospective, randomized controlled interventional experimental study. Cefuroxime was chosen as the PBP-3-active antibiotic and tobramycin represented the aminoglycosides. The animals were randomized to receive (I) bacteria killed by cefuroxime, (II) live bacteria, (III) bacteria killed by heat, or (IV) bacteria killed by the combination of cefuroxime and tobramycin. Plasma endotoxin, tumor necrosis factor alpha, interleukin-6, interleukin-10, leukocytes, and organ function were recorded at the start of the experiment and then hourly for 6 h.

resultsDifferences in dynamics of concentration over time between the four treatment groups were found for the three cytokines (p < 0.001). Animals receiving cefuroxime-killed bacteria demonstrated higher responses than those receiving live (p < 0.05) or heat-killed bacteria (p < 0.01). The addition of tobramycin reduced the cefuroxime-induced responses (p < 0.001). The cytokine responses were associated with leucocyte activation that was further associated with pulmonary dysfunction and increases in lactate (p < 0.01).

conclusionsIn comparison with live or heat-killed bacteria, bacteria killed by a PBP-3-active antibiotic induced an increased inflammatory response that appears to be associated with deteriorated organ and cellular function. The addition of an aminoglycoside to the PBP-3-active antibiotic reduced that response.

Indexed as

AnimalsCefuroximeDisease Models, AnimalEndotoxinsEscherichia coliEscherichia coli InfectionsInflammationInterleukin-10Interleukin-6Multiple Organ FailureOrgan Dysfunction ScoresPenicillin-Binding ProteinsProspective StudiesSepsisSwineTobramycinCefuroximeEndotoxinsInterleukin-10Interleukin-6Penicillin-Binding ProteinsTobramycinTumor Necrosis Factor-alphaAntibioticsBacteriaCytokinesInflammationPorcineSepsis

Identifiers

PMID33189146
PMCPMC7666448
OpenAlexW3104356433

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.